SINO MEDICAL SCIENCES TECHNOLOGY INC. Sino Medical Sciences Technology Inc. Stock
Equities
688108
CNE100003NY2
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12.37 CNY | +3.51% |
|
+1.56% | -1.43% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 193M 26.7M | Sales 2023 | 343M 47.52M | Capitalization | 5.15B 712M |
|---|---|---|---|---|---|
| Net income 2022 | -162M -22.43M | Net income 2023 | -39M -5.4M | EV / Sales 2022 | 11.4 x |
| Net cash position 2022 | 145M 20.09M | Net Debt 2023 | 10.85M 1.5M | EV / Sales 2023 | 15 x |
| P/E ratio 2022 |
-14.3
x | P/E ratio 2023 |
-126
x | Employees | 652 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 67.6% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.51% | ||
| 1 week | +1.56% | ||
| Current month | +7.85% | ||
| 1 month | +21.51% | ||
| 3 months | +30.62% | ||
| 6 months | -11.39% | ||
| Current year | -1.43% |
1 week
11.05
12.65
1 month
9.6912.65
Current year
7.4413.40
1 year
7.4414.85
3 years
4.6014.85
5 years
4.6043.60
10 years
4.6043.60
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Hua Sun
CEO | Chief Executive Officer | 63 | 07-09-20 |
Li Hua Shen
DFI | Director of Finance/CFO | 52 | 12-12-31 |
Wen Tian
BRD | Director/Board Member | 41 | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rui Li
BRD | Director/Board Member | 46 | 20-12-29 |
Yan Gao
BRD | Director/Board Member | 58 | 20-06-18 |
Jian Hua Sun
CEO | Chief Executive Officer | 63 | 07-09-20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 12.37 | +3.51% | 9,785,280 |
| 24-05-16 | 11.95 | +2.05% | 8,216,674 |
| 24-05-15 | 11.71 | +2.63% | 8,180,735 |
| 24-05-14 | 11.41 | +1.15% | 7,127,449 |
| 24-05-13 | 11.28 | -7.39% | 11,493,330 |
End-of-day quote Shanghai S.E., May 16, 2024
More quotes
Sino Medical Sciences Technology Inc is a China-based company mainly engaged in the research, development, production and sales of high-end interventional medical devices. The Company's product pipeline covers the field of interventional therapy such as cardiovascular, cerebrovascular, and structural heart disease. The Company's main products include coronary drug stent system and balloon dilatation catheters. The Company conducts its businesses within the domestic market and overseas markets, and it has subsidiaries in Beijing, China, Hong Kong, China, the United States, Japan, the Netherlands, and France.
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -1.43% | 702M | |
| -5.10% | 11.34B | |
| +4.02% | 9.11B | |
| +38.12% | 5.53B | |
| -23.70% | 4.61B | |
| +8.55% | 3.45B | |
| -6.44% | 2.87B | |
| -5.85% | 2.1B | |
| -11.84% | 2.08B | |
| -23.36% | 1.78B |
- Stock Market
- Equities
- 688108 Stock
